5 Robotics Stocks Billionaires Are Loading Up On

3. Intuitive Surgical, Inc. (NASDAQ:ISRG)

Number of Hedge Fund Holders: 67

Number of Billionaire Investors: 15

Intuitive Surgical, Inc. (NASDAQ:ISRG) is among the leading robotics stocks that have captured the attention of billionaires. Intuitive Surgical, Inc. (NASDAQ:ISRG) is known for its advanced robotics capabilities in the field of medical technology. The company has developed and commercialized the da Vinci Surgical System, a robotic-assisted surgical platform that enables minimally invasive procedures. As of Q1 2023, Intuitive Surgical, Inc. (NASDAQ:ISRG) shares were held by 15 billionaires.

On May 31, Lee Hambright, an analyst at Bernstein, increased the price target for Intuitive Surgical, Inc. (NASDAQ:ISRG) to $365 from $350 while maintaining an Outperform rating on the shares. The analyst highlighted a new marketing video that showcases Intuitive Hub and the company’s increasing emphasis on learning and services. Bernstein stated that Intuitive Surgical, Inc. (NASDAQ:ISRG) continues to be the most compelling long-term growth story in their coverage.

According to Insider Monkey’s first quarter database, 67 hedge funds were long Intuitive Surgical, Inc. (NASDAQ:ISRG), compared to 70 funds in the earlier quarter. Billionaire Ray Dalio’s Bridgewater Associates held a prominent stake in the company, comprising 521,790 shares worth $133.3 million. 

RiverPark Large Growth Fund made the following comment about Intuitive Surgical, Inc. (NASDAQ:ISRG) in its Q1 2023 investor letter:

“Intuitive Surgical, Inc. (NASDAQ:ISRG): ISRG shares were a top detractor in the quarter despite 4Q results largely in line with expectations. The company used the quarterly release to define the timeline of upcoming products including its next-gen platform, now expected next year. The market was disappointed by this timing.

Intuitive is the pioneer and clear leader in robotic surgery and remains one of our most compelling long-term growth opportunities. The company’s products address a massive market with very low current penetration, and the company has a strong moat. Its major competitors, J&J and Medtronic, are facing large delays (to at least 2024) in introducing their platforms as the FDA approval process has become more difficult. These delays give Intuitive more time to place systems, train surgeons and launch new products, extending its competitive advantage. The company’s “Extended Use Program” aims to make its tools more price-competitive to traditional non-robotic procedures, which increases the company’s moat.”